Abstract 2743
Background
Targeted therapies (TT), combo-immunotherapy (CMI) and mono-immunotherapy (MI) in combination (CRI) or not with radiotherapy are commonly used in patients with melanoma brain metastases (MBMs), but studies that directly compare these strategies are lacking. This meta-analysis aimed to better elucidate their activity and efficacy.
Methods
A systematic search of Medline, Embase and conferences proceedings up to January 2019 was carried out to identify trials investigating combo TT, mono TT, MI, CMI, CRI in MBMs. The outcomes considered were progression free survival (PFS), overall survival (OS) and objective response rate (ORR) evaluated at both intra and extra-cranial sites. Random effects models were used to compare the different therapeutic strategies.
Results
We included 15 trials, which provided 1132 patients for analyses. CMI showed a statistically significant better OS than MI (p = 0.03, p = 0.05, p = 0.03 at 6, 18 and 24 months respectively) and combo TT (p = 0.04, p = 0.03, at 18 and 24 months respectively). CMI showed a statistically significant better PFS compared to combo TT (p < 0.001 at 12 and 18 months), MI (p = 0.02, p < 0.02 and p = 0.05 at 6, 12 and 18 months respectively) and mono TT (p < 0.001 at 6, 12 and 18 months respectively). The intracranial ORR was higher with CMI compared to mono TT (p < 0.001) and MI (p < 0.001), while there was no difference between CMI and combo TT.
Conclusions
This meta-analysis suggests that CMI increases long term PFS and OS compared to MI and combo TT. Combo TT and CMI are associated with a similar intracranial response rate. The role systemic therapy in combination with radiotherapy remains to be better elucidated.
Clinical trial identification
Not applicable
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract
1885 - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
5259 - Integrative RNAseq and Target panel sequencing reveals common and distinct innate and adaptive resistance mechanisms to BRAF inhibitors
Presenter: Phil Cheng
Session: Poster Display session 3
Resources:
Abstract
5619 - Effective treatment with T-VEC monotherapy in Stage IIIB/C-IVM1a Melanoma of the Head & Neck Region
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
5666 - Re-introduction of T-VEC Monotherapy in Recurrent Stage IIIB/C-IVM1a melanoma is effective
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
4117 - Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): subgroup analysis of the phase 3 OPTiM study
Presenter: Mark Middleton
Session: Poster Display session 3
Resources:
Abstract
5303 - Real Life Use of Talimogene Laherparepvec in Melanoma in Centers in Austria and Switzeland
Presenter: Christoph Hoeller
Session: Poster Display session 3
Resources:
Abstract
4130 - Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
2050 - Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)
Presenter: Sarah Knispel
Session: Poster Display session 3
Resources:
Abstract
1618 - Comparative-Effectiveness of Pembrolizumab vs. Nivolumab for Patients with Metastatic Melanoma
Presenter: Justin Moser
Session: Poster Display session 3
Resources:
Abstract